Biopharma
By
Adaptive Biotechnologies and Pfizer Announce Strategic Research Collaboration Valued Up to $890 Million to Advance Breakthrough Therapies for Rheumatoid Arthritis and Immune-Mediated Diseases
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis. A data licensing agreement to…
Will BioNTech and Pfizer’s Counterstrike Against GSK Reshape Europe’s Largest mRNA Patent War?
Key Insights GSK’s Offensive Meets Resistance GSK launched a sweeping litigation campaign in 2024, targeting BioNTech and Pfizer…
Can LB Pharmaceuticals’ $285M IPO Reignite Investor Confidence in Biotech After Months of Silence?
Key Insights IPO Breaks Market Drought LB Pharmaceuticals, a CNS-focused biotech, has defied a months-long IPO drought by…
Is Merck’s £1B Exit Forcing AstraZeneca, Lilly, and Sanofi to Rethink UK’s Life Sciences Future?
Key Insights Merck Triggers Domino Effect with £1B Withdrawal Merck’s decision to abandon its £1-billion London R&D facility…
U.S. FDA Approves JASCAYD® for Progressive Pulmonary Fibrosis – A New Treatment Option for Adults?
Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has approved JASCAYD® (nerandomilast) tablets for the…
Has the FDA Approval of Breyanzi Expanded CAR T Cell Therapy Options for Marginal Zone Lymphoma Patients?
Bristol Myers Squibb has received approval from the U.S. Food and Drug Administration for Breyanzi, a CD19-directed CAR…
